Literature DB >> 30301825

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis.

Harry H Yoon1, Qian Shi2, Erica N Heying2, Andrea Muranyi3, Joerg Bredno3, Faith Ough3, Azita Djalilvand3, June Clements3, Rebecca Bowermaster3, Wen-Wei Liu3, Michael Barnes3, Steven R Alberts4, Kandavel Shanmugam3, Frank A Sinicrope1.   

Abstract

PURPOSE: Colorectal cancers with deficient DNA mismatch repair (dMMR) are presumed to uniformly have dense lymphocytic infiltration that underlies their favorable prognosis and is critical to their responsiveness to immunotherapy, as compared with MMR-proficient (pMMR) tumors. We examined T-cell densities and their potential heterogeneity in a large cohort of dMMR tumors. EXPERIMENTAL
DESIGN: CD3+ and CD8+ T-cell densities were quantified at the invasive margin (IM) and tumor core (CT) in 561 stage III colon cancers (dMMR, n = 278; pMMR, n = 283) from a phase III adjuvant trial (N0147). Their association with overall survival (OS) was determined using multivariable Cox analysis.
RESULTS: Although CD3+ and CD8+ T-cell densities in the tumor microenvironment were higher in dMMR versus pMMR tumors overall, intertumoral heterogeneity in densities between tumors was significantly higher by 30% to 88% among dMMR versus pMMR cancers (P < 0.0001 for all four T-cell subtypes [CD3+IM, CD3+CT, CD8+IM, CD8+CT]). A substantial proportion of dMMR tumors (26% to 35% depending on the T-cell subtype) exhibited T-cell densities as low as that in the bottom half of pMMR tumors. All four T-cell subtypes were prognostic in dMMR with CD3+IM being the most strongly prognostic. Low (vs. high) CD3+IM was independently associated with poorer OS among dMMR (HR, 4.76; 95% confidence interval, 1.43-15.87; P = 0.0019) and pMMR tumors (P = 0.0103).
CONCLUSIONS: Tumor-infiltrating T-cell densities exhibited greater intertumoral heterogeneity among dMMR than pMMR colon cancers, with CD3+IM providing robust stratification of both dMMR and pMMR tumors for prognosis. Potentially, lower T-cell densities among dMMR tumors may contribute to immunotherapy resistance. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30301825      PMCID: PMC6320300          DOI: 10.1158/1078-0432.CCR-18-1984

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Authors:  Mohamed Amgad; Elisabeth Specht Stovgaard; Eva Balslev; Jeppe Thagaard; Weijie Chen; Sarah Dudgeon; Ashish Sharma; Jennifer K Kerner; Carsten Denkert; Yinyin Yuan; Khalid AbdulJabbar; Stephan Wienert; Peter Savas; Leonie Voorwerk; Andrew H Beck; Anant Madabhushi; Johan Hartman; Manu M Sebastian; Hugo M Horlings; Jan Hudeček; Francesco Ciompi; David A Moore; Rajendra Singh; Elvire Roblin; Marcelo Luiz Balancin; Marie-Christine Mathieu; Jochen K Lennerz; Pawan Kirtani; I-Chun Chen; Jeremy P Braybrooke; Giancarlo Pruneri; Sandra Demaria; Sylvia Adams; Stuart J Schnitt; Sunil R Lakhani; Federico Rojo; Laura Comerma; Sunil S Badve; Mehrnoush Khojasteh; W Fraser Symmans; Christos Sotiriou; Paula Gonzalez-Ericsson; Katherine L Pogue-Geile; Rim S Kim; David L Rimm; Giuseppe Viale; Stephen M Hewitt; John M S Bartlett; Frédérique Penault-Llorca; Shom Goel; Huang-Chun Lien; Sibylle Loibl; Zuzana Kos; Sherene Loi; Matthew G Hanna; Stefan Michiels; Marleen Kok; Torsten O Nielsen; Alexander J Lazar; Zsuzsanna Bago-Horvath; Loes F S Kooreman; Jeroen A W M van der Laak; Joel Saltz; Brandon D Gallas; Uday Kurkure; Michael Barnes; Roberto Salgado; Lee A D Cooper
Journal:  NPJ Breast Cancer       Date:  2020-05-12

Review 2.  Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.

Authors:  Darleny Y Lizardo; Chaoyuan Kuang; Suisui Hao; Jian Yu; Yi Huang; Lin Zhang
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-06       Impact factor: 10.680

Review 3.  Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.

Authors:  Zhaohui Jin; Frank A Sinicrope
Journal:  J Clin Oncol       Date:  2022-06-01       Impact factor: 50.717

4.  Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).

Authors:  H Lee; D Sha; N R Foster; Q Shi; S R Alberts; T C Smyrk; F A Sinicrope
Journal:  Ann Oncol       Date:  2020-01-25       Impact factor: 32.976

5.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

Authors:  Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope
Journal:  Cancer Discov       Date:  2020-11-02       Impact factor: 38.272

6.  Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients.

Authors:  Dan Wang; Weina Yu; Jingyao Lian; Qian Wu; Shasha Liu; Li Yang; Feng Li; Lan Huang; Xinfeng Chen; Zhen Zhang; Aitian Li; Jinbo Liu; Zhenqiang Sun; Junxia Wang; Weitang Yuan; Yi Zhang
Journal:  J Hematol Oncol       Date:  2020-06-05       Impact factor: 17.388

Review 7.  Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

Authors:  François Ghiringhelli; Jean-David Fumet
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

Review 8.  Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?

Authors:  Nicolas Huyghe; Paméla Baldin; Marc Van den Eynde
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-11-25

9.  Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status.

Authors:  Douglas J Hartman; Madison Frank; Lindsey Seigh; Haroon Choudry; James Pingpank; Matthew Holtzman; David Bartlett; Nathan Bahary; Liron Pantanowitz; Reetesh K Pai
Journal:  Am J Surg Pathol       Date:  2020-07       Impact factor: 6.298

Review 10.  Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Authors:  Mohamed Amgad; Elisabeth Specht Stovgaard; Eva Balslev; Jeppe Thagaard; Weijie Chen; Sarah Dudgeon; Ashish Sharma; Jennifer K Kerner; Carsten Denkert; Yinyin Yuan; Khalid AbdulJabbar; Stephan Wienert; Peter Savas; Leonie Voorwerk; Andrew H Beck; Anant Madabhushi; Johan Hartman; Manu M Sebastian; Hugo M Horlings; Jan Hudeček; Francesco Ciompi; David A Moore; Rajendra Singh; Elvire Roblin; Marcelo Luiz Balancin; Marie-Christine Mathieu; Jochen K Lennerz; Pawan Kirtani; I-Chun Chen; Jeremy P Braybrooke; Giancarlo Pruneri; Sandra Demaria; Sylvia Adams; Stuart J Schnitt; Sunil R Lakhani; Federico Rojo; Laura Comerma; Sunil S Badve; Mehrnoush Khojasteh; W Fraser Symmans; Christos Sotiriou; Paula Gonzalez-Ericsson; Katherine L Pogue-Geile; Rim S Kim; David L Rimm; Giuseppe Viale; Stephen M Hewitt; John M S Bartlett; Frédérique Penault-Llorca; Shom Goel; Huang-Chun Lien; Sibylle Loibl; Zuzana Kos; Sherene Loi; Matthew G Hanna; Stefan Michiels; Marleen Kok; Torsten O Nielsen; Alexander J Lazar; Zsuzsanna Bago-Horvath; Loes F S Kooreman; Jeroen A W M van der Laak; Joel Saltz; Brandon D Gallas; Uday Kurkure; Michael Barnes; Roberto Salgado; Lee A D Cooper
Journal:  NPJ Breast Cancer       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.